

14. The method of claim 1, wherein the analyte is a biomarker.
15. The method of claim 1, wherein the analyte is a drug.
16. The method of claim 1, wherein the profile is based on the patient's own previous pharmacodynamic, pharmacokinetic, or pharmacogenetic profiles. 5
17. The method of claim 1, wherein the analyte is a pro-drug.
18. The method of claim 1, wherein the analyte is a drug metabolite. 10
19. The method of claim 1, wherein the analyte is a metabolite.
20. The method of claim 2 wherein the protocol to be run on by said reader assembly is stored on said external device.
21. The method of claim 20 further comprising transmitting the protocol from the external device to the fluidic device. 15
22. The method of claim 1 wherein the known profile is stored on said external device.
23. The method of claim 1 wherein the protocol is associated with said patient and comprises a time and/or date to test said sample of bodily fluid. 20
24. The method of claim 1 further comprising indicating that multiple doses of the therapeutic agent have been taken when a metabolite concentration detected by the reader assembly is at an elevated level compared to a known profile. 25
25. The method of claim 1 further comprising indicating that insufficient doses of the therapeutic agent have been taken when a metabolite concentration detected by the reader assembly is at a decreased level compared to a known profile.
26. The method of claim 1 wherein the patient is notified automatically after the signal is compared with a known profile. 30

\* \* \* \* \*